KDL Biotech (Delisted) financials and balance sheet

BSE: 532291

Formerly Kopran Drugs

Last traded ₹2.14 on 16 Mar 2015

Delisted on 11 May 2018.

5 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to September, then March.KDL Biotech annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Peak revenue ₹41 Cr, year to Sep 2008A loss in 4 of the 4 years with results on record

Operating and net margin, per cent

  • Operating margin
  • Net margin

The company moved its year end from September to March: its last year to September on record ended in Sep 2008, its first year to March in Mar 2011.

Results for the year to Mar 2013

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue21
  2. Materials and goods−5.0
  3. Employee costs−8.8
  4. Other expenses−9.6
  5. Operating profit−2.8
  6. Depreciation−6.9
  7. Other income+0.4
  8. Finance costs−6.9
  9. Profit before tax−16
  10. Net profit−16

Profit and loss

Standalone, ₹ crore, years to September, then March. No results on record for the year to Mar 2010.KDL Biotech quarterly results

₹ croreSep 2008Mar 2010Mar 2011Mar 2012Mar 2013
Revenue from operations41.4–28.426.520.5
66.3–40.9–23.3
Materials and goods bought36.7–6.74.75.0
Employee costs7.9–––8.8
Other expenses21.7–––9.6
Operating profit before depreciation−24.9–−12.5–−2.8
Operating margin−60.3%–−43.9%–−13.7%
Materials, % of revenue88.7%–––24.2%
Employee costs, % of revenue19.2%–––42.8%
Other expenses, % of revenue52.4%–––46.6%
Depreciation and amortisation6.9–9.5–6.9
Operating profit after depreciation−31.8–−22.0–−9.7
Other income21.1–0.50.80.4
Finance costs10.3–6.76.86.9
Profit before one-off items and tax−21.1–−28.2−17.2−16.2
One-off items––−11.5––
Profit before tax−21.1–−39.7−17.2−16.2
Tax0.0–7.7––
Net profit−21.1–−61.4−17.2−16.2
Net margin−51.1%–−216.0%−65.0%−78.9%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2011 they do not, so they are left blank. Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the year to Mar 2012: the statement does not state its depreciation, which operating profit is worked out from, so operating profit is not given.

Per share

Standalone, ₹ per share, years to September, then March.

₹ per shareMar 2012Mar 2013
Earnings per share−₹7.16−₹6.74
Diluted earnings per share−₹7.16−₹6.74
Market cap at the year end (₹ crore)9.614.57

Ratios

Standalone, years to September, then March.

RatioMar 2012Mar 2013
Revenue growth−6.8%−22.4%
Interest cover is left blank for the years to Sep 2008, Mar 2011 and Mar 2013: operating profit after depreciation is a loss, and a loss covers no interest bill.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2013.

Measure3 years
Operating margin, average−28.8%
Net margin, average−120.0%